Carl Johan Kördel
Chief Executive Officer at Chori Pars AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christine Soden | F | 66 |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 9 years |
| John Brown | M | 69 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Ed Borkowski | M | 64 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Anders Bergman | M | 60 |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Nils Olof Jarlman | M | 70 |
University of Lund
| 4 years |
| Bengt Arvid Westrin | M | 66 |
University of Lund
| 29 years |
| Inge Pettersson | M | 77 |
University of Lund
| 16 years |
| Knut Pettersson | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Olov Arvid Sterner | M | 71 |
University of Lund
| 4 years |
| Anna Carina Schmidt | F | 66 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Inga Sarah Maria Fredriksson | M | 56 |
University of Lund
| 4 years |
| Lars-Erik Magnus Wernersson | M | 56 |
University of Lund
| 23 years |
| James Hall | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Petter Pilesjö | M | - |
University of Lund
| - |
| Anna Haupt | F | - |
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm.
University of Lund
| 9 years |
| Iliam Barkino | M | - |
Industrifonden
Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | 3 years |
| Gunnar Olof Olsson | M | 71 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Ronald W. Pero | M | - |
University of Lund
| - |
| Petr Dejmek | M | 79 |
University of Lund
| 35 years |
| Ebba Cecilia Fåhraeus | F | 61 |
University of Lund
| 9 years |
| Peter Leander | M | 67 |
University of Lund
| - |
| Andreas Konar | M | 75 |
University of Lund
| - |
| Stig Steen | M | 76 |
University of Lund
| - |
| Roland Andersson | M | 69 |
University of Lund
| 24 years |
| Rajni Hatti-Kaul | M | 65 |
University of Lund
| 20 years |
| Catharina Svanborg | M | 75 |
University of Lund
| 35 years |
| Matti Zemack | M | 51 |
Industrifonden
Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | 3 years |
| Karin Leandersson | F | 52 |
University of Lund
| - |
| Christer Thordson | M | 66 |
University of Lund
| - |
| Bill Hansson | M | - |
University of Lund
| - |
| Magnus Fontes | M | 61 |
University of Lund
| - |
| Lena Mårtensson | M | 70 |
University of Lund
| - |
| Viktor Öwall | M | 69 |
University of Lund
| - |
| Björn Kettilsson Wullt | M | 68 |
University of Lund
| - |
| Jonas Hafström | M | - |
University of Lund
| - |
| Gabriela Godaly | F | - |
University of Lund
| - |
| Susanne Kristensson | F | - |
University of Lund
| - |
| Annika Maria Olsson | M | 62 |
University of Lund
| - |
| Boris Zhmud | M | - |
University of Lund
| - |
| Ingegerd Monica Sjöholm | F | 75 |
University of Lund
| - |
| Jan-Erik Solem | M | - |
University of Lund
| - |
| Svein Arild Mathisen | M | 68 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Lars Gösta Montelius | M | 66 |
University of Lund
| - |
| Klas Rune Arildsson | M | 64 |
University of Lund
| - |
| Ingrid Anne-Marie Pålsson | M | 73 |
University of Lund
| - |
| Tomas Leanderson | M | 68 |
University of Lund
| 34 years |
| Jan Erik Ragnar Söderberg | M | 68 |
University of Lund
| - |
| Sven Fredrik Tiberg | M | 61 |
University of Lund
| - |
| Fredrik Höök | M | - |
University of Lund
| 20 years |
| Stina Margareta Gestrelius | M | 75 |
University of Lund
| - |
| Artur Schmidtchen | M | - |
University of Lund
| - |
| Sten Gunnar Otto Skolling | M | 62 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Peter Spégel | M | 47 |
University of Lund
| - |
| Lars Christer Oxelheim | M | 80 |
University of Lund
| - |
| Lars Magnus Thomas Bjursten | M | 75 |
University of Lund
| 35 years |
| Jing Liu | M | 53 |
University of Lund
| - |
| Gustaf Olsson | M | 84 |
University of Lund
| 18 years |
| Mona Annelie Sylvén-Troedsson | F | 75 |
University of Lund
| - |
| Hakon Leffler | M | - |
University of Lund
| - |
| Tommy Evert Andersson | M | 68 |
University of Lund
| 28 years |
| Guido Zacchi | M | 74 |
University of Lund
| 35 years |
| Peter Jelkeby | M | 61 |
University of Lund
| - |
| Signhild Lou E Arnegård-Hansen | F | 64 |
University of Lund
| - |
| Michael Owens | M | 68 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Carl-Henric Lennart Nilsson | M | 64 |
University of Lund
| - |
| Javier Linares-Pastén | M | 60 |
University of Lund
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Grey | M | 71 |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 6 years |
| Patrick Volkert Vink | M | 60 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | 4 years |
| Maria Sjöberg | M | 60 | - | |
| Carl Henrik Palm | M | 66 | - | |
| Barbara Dalton | M | 69 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 2 years |
| Julian Gilbert | M | 63 | 12 years | |
| Hans Bo Göran Wessman | M | 76 | 5 years | |
| Filip Tobias Petersson | M | 47 |
University of Lund
| 10 years |
| Michael Green | M | - |
University of Lund
| 8 years |
| Marten Steen | M | 49 |
University of Lund
| 9 years |
| Lars Thomas Lidgren | M | 53 |
University of Lund
| 6 years |
| Per Stefan Andersson-Engels | M | 64 |
University of Lund
| 3 years |
| Lars Bertil Christer Wingren | M | 58 |
University of Lund
| 8 years |
| Mats Gunnar Pettersson | M | 78 |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 6 years |
| Linda Mellby | M | - |
University of Lund
| 5 years |
| Fredrik Häglund | M | 49 |
University of Lund
| 6 years |
| Rikard Krook | M | 57 |
University of Lund
| 5 years |
| Magnus Eriksson | M | - |
University of Lund
| 4 years |
| Boman Lyngfelt | M | - |
University of Lund
| 5 years |
| Robin Egerot | M | - |
University of Lund
| 4 years |
| John Erik Syrén | M | 46 |
University of Lund
| 3 years |
| Karl Hampus Jakobsson | M | 45 |
University of Lund
| 4 years |
| Sandra Heidmann | F | - |
University of Lund
| 4 years |
| Måns Nicklas Lidgren | M | 47 |
University of Lund
| 5 years |
| Peter Sandin | M | 57 |
University of Lund
| 4 years |
| Patrik Romberg | M | 58 |
University of Lund
| 6 years |
| Thomas Neckmar | M | - |
University of Lund
| 1 years |
| Dario Kriz | M | 58 |
University of Lund
| 3 years |
| Martin Magnusson | M | - |
University of Lund
| 3 years |
| Bengt Karlsson | M | - |
University of Lund
| 5 years |
| Folke Per-Olof Wallström | M | 75 | - | |
| Margaret von Platen | F | 65 | - | |
| Lars Christer Fedrik Fåhraeus | M | 59 | 4 years | |
| Ulrika Ringdahl | F | - |
University of Lund
| 11 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 93 | 93.00% |
| United Kingdom | 5 | 5.00% |
| United States | 2 | 2.00% |
| Denmark | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carl Johan Kördel
- Personal Network
